Maynard Um
-
-
-
-
-
-
-
CervoMed shows biomarker improvements in dementia trial
-
-
-
-
-
-
-
CervoMed (CRVO) PT Raised to $27 at Canaccord Genuity
-
-
-
-
-
-
-
D. Boral Capital Upgrades CervoMed (CRVO) to Buy
-
-
-
-
-
-
-
CervoMed (CRVO) Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
-
-
-
-
-
-
-
Chardan Capital Markets Starts CervoMed (CRVO) at Buy
-
-
-
-
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

